CEO Executive AssistantIPO preparation is the period in a biotech CEO’s career that is most often described in retrospect as simultaneously the most demanding and the most consequential. The company must be operated at normal performance while the CEO and senior leadership team are simultaneously building the S-1 narrative, preparing management presentation materials, conducting investor education, and managing the diligence requirements of the underwriting process.
The time management challenge is not simply volume, though volume is significant. It is the quality of thinking required across two distinct tracks: the operational track, where a clinical-stage or commercial-stage biotech still needs to deliver on its program milestones, and the investor education track, where the CEO is creating the public market narrative that will shape how the company is valued for years.
Understanding the IPO Timeline’s Demands on the CEO
A typical IPO preparation timeline for a biotech runs 6 to 9 months from the decision to proceed to the public offering. The timeline compresses into increasingly intense phases: early preparation and S-1 drafting, SEC comment resolution, investor education and the road show, and pricing.
The CEO’s time allocation shifts significantly across these phases. Early preparation is primarily organizational: ensuring the company has the public company infrastructure in place (audit committee, independent board members, financial controls, investor relations capability), the scientific narrative is clearly articulated, and the S-1 content is ready to draft. The CEO’s contribution here is conceptual and strategic: providing the pipeline valuation rationale, the market opportunity framing, and the clinical development strategy that will appear in the prospectus.
The S-1 drafting phase is where CEO time demand spikes. The registration statement is a legal document, but its strategic content, including the risk factors, the business description, the clinical development program narrative, and the management discussion, requires CEO voice and judgment. The CEO will spend significant time in review sessions with counsel, underwriters, and the CFO working through draft language.
The road show, typically a two-week period immediately before pricing, is the most concentrated CEO time demand in the process. It involves multiple investor meetings per day, in multiple cities, with the CEO carrying the presentation and fielding investor questions. No amount of preparation fully replaces the experience of doing it, but the CEOs who perform best in road show meetings are those who have internalized the narrative rather than memorized the deck.
Running the Company While Preparing the IPO
The operational business does not pause for the IPO. Clinical trials in enrollment are still enrolling. Data packages expected at specific milestones are still expected. Regulatory interactions continue. Key hires still need to be made. And the leadership team needs to continue performing at the level that the IPO narrative promises investors.
The most common operational failure mode during IPO preparation is the CEO’s unintended withdrawal from operational leadership. The IPO process demands so much time that the CEO becomes less available, leadership team meetings become shorter or less frequent, and direct reports begin managing around the CEO rather than through them.
The corrective discipline is to treat the regular operating cadence as protected during the IPO process, not flexible. Leadership team meetings stay on the calendar. One-on-ones with direct reports remain weekly. Clinical program reviews continue on schedule. These are the mechanisms that keep the company running at the level the S-1 is representing to potential investors.
Delegating Operational Authority During IPO
IPO preparation is the right time to test whether the biotech CEO has built a leadership team capable of running the business without constant CEO intervention. It is not the right time to discover they cannot.
Before the IPO preparation window opens, the CEO should explicitly expand operational authority for the CFO, CMO, and other C-suite leaders to make decisions that would normally require CEO sign-off. This is not abdicating leadership. It is calibrating authority to the reality of CEO bandwidth and creating the organizational muscle that will serve the company well as a public company, where the CEO’s investor relations demands will remain elevated permanently.
The S-1 Narrative: The CEO’s Most Important Document
The S-1 registration statement is, in many respects, the CEO’s most consequential public communication. It will be read by every institutional investor considering the offering, by every analyst covering the company, by prospective employees, partners, and acquirers, and by the regulatory community. It is a legal document, but its persuasiveness, clarity, and scientific credibility depend on the CEO’s voice and judgment.
CEOs who treat S-1 drafting as a process managed by counsel and the CFO with minimal personal involvement tend to produce documents that are legally sound but narratively weak. The business description section, the pipeline overview, and the clinical development strategy narrative are places where CEO directness and strategic clarity make a significant difference.
A useful practice is to write a plain-language version of the core investment thesis before the S-1 drafting begins. One page, no legal language, answering: What disease are we treating, why is it important, what have we shown the drug can do, why do we believe we can develop it successfully, and why is this company the one to do it? That document becomes the north star for the S-1 narrative and the road show deck.
Investor Education: Before the Road Show Matters More
The most effective biotech IPO CEOs begin investor education well before the road show, often 6 to 12 months before the anticipated offering. They build relationships with key healthcare-focused institutions through conference presentations, one-on-one meetings at scientific meetings, and introductions through board members and existing investors.
This pre-IPO investor education serves two purposes. It builds genuine understanding of the science among the investors who will be making the largest allocation decisions, and it provides the CEO with calibration on how the investment thesis is received and where the skepticism lies.
The skepticism is valuable. Investors who push back on the efficacy data interpretation, the market sizing assumption, or the competitive differentiation argument in pre-IPO conversations are giving the CEO the chance to sharpen the narrative before it is delivered under the pressure of a live road show.
For a deeper framework on managing executive time during high-stakes external communication periods, see pharma CEO time management.
Identifying the Key Investor Questions
Every biotech IPO faces a specific set of skeptical questions that will be asked repeatedly in road show meetings. For a clinical-stage oncology company, it might be the clinical endpoint selection rationale. For a platform technology company, it might be the evidence that the platform has therapeutic applicability beyond the lead program. For a company with a novel mechanism, it might be the target validation story.
The CEO should identify the four or five hardest questions the company will face, prepare rigorous and honest answers, and practice delivering those answers fluently before the road show. The investors who ask the hardest questions in road show meetings are often the largest potential allocators. Credible answers under pressure are a signal of organizational quality.
Harvard Business Review’s analysis of biotech investor communication suggests that CEO credibility and scientific transparency are among the strongest predictors of IPO performance and post-IPO institutional retention.
Managing the Underwriting Team
The underwriting team, including the lead banks and co-managers, brings significant IPO process experience but also significant demands on CEO time. Roadshow preparation meetings, pricing strategy discussions, and investor relationship introductions from the banks can collectively consume more time than the CEO has available if not actively managed.
A useful practice is to assign a single internal point of contact, typically the CFO or head of investor relations, as the primary interface with the underwriting team for all process and preparation matters. The CEO’s direct involvement with the underwriters should be concentrated on strategic decisions: the investor targeting strategy, the pricing range rationale, and the management of any investor-specific concerns that require CEO engagement.
Clinical Data and IPO Timing
Biotech IPOs are profoundly affected by clinical data timing. The IPO window that opens following positive early-stage data, and the IPO window that might be forced by a cash position that cannot wait for the next data readout, create very different strategic contexts for the CEO.
The CEO’s judgment on IPO timing, and the honest communication of that timing rationale to the board, is a decision of significant consequence. An IPO that prices well but occurs before a data readout that would substantially increase valuation may generate capital at a cost to the company’s long-term shareholder base. An IPO that is delayed while waiting for a better data moment may run the company into a cash position that reduces negotiating leverage.
These timing judgments require the CEO to hold a sophisticated view of clinical program timelines, market window dynamics, and capital structure simultaneously. They are not decisions where the investment bankers’ incentives are fully aligned with the company’s long-term interests.
For more on building the executive support infrastructure to manage complex scheduling and preparation demands during high-intensity periods, see hiring an executive assistant for pharma CEOs.
The Transition to Public Company Leadership
The IPO is not the end of the time management challenge. It is the beginning of a permanent elevation in investor relations and public company governance demands. The quarterly earnings cycle, the SEC disclosure obligations, and the expanded analyst and investor engagement requirements all represent a structural increase in CEO time allocation that is permanent.
The biotech CEO who treats the IPO as an event, rather than a transition to a fundamentally different operating context, is typically surprised by how much the public company obligations compress the time available for internal leadership and R&D oversight.
Planning for that transition, building investor relations capability, hiring IR professionals, and establishing the public company governance infrastructure before the offering, is the final and often underinvested component of IPO preparation. The CEO who walks off the road show and into a fully functional public company infrastructure is far better positioned than the one walking into a company that is still configured as a private startup.
Related Reading
For further context, explore How Biopharma CEOs Manage Time During Merger and Acquisition Due Diligence and How Biosimilar Company CEOs Manage Time Across Development and Market Access.